Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Unknown 1Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 23INDUSTRY 22FED 3INDIV 1

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3

Conditions

Prostatic Neoplasms 3Carcinoma, Non-Small-Cell Lung 2Turcot syndrome 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Neoplasm Metastasis 1Lung Neoplasms 1

Interventions

enzalutamide 4pembrolizumab 3Docetaxel 3apalutamide 2Testosterone 2Prednisone 2Cholecalciferol 2Celecoxib 2Androgen Antagonists 2Abiraterone Acetate 22-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 2relugolix 1olaparib 1nilutamide 1histrelin 1gallium 68 PSMA-11 1capivasertib 1bicalutamide 1acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 1abiraterone 1Yoga 1Triptorelin Pamoate 1Tablets 1Simvastatin 1Sildenafil Citrate 1Pluvicto 1Perioperative Care 1Pentoxifylline 1Methylprednisolone 1Leuprolide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
FED × Prostatic Neoplasms × pembrolizumab × Clear all
NCT04104893 2026-02-27

CHOMP

VA Office of Research and Development

Phase 2 Active not recruiting
40 enrolled
Genitourinary

Turcot syndrome, Prostatic Neoplasms

NCT04116775 2022-06-23

Fecal Microbiota Transplant and Pembrolizumab for Men With Metastatic Castration Resistant Prostate Cancer.

Portland VA Medical Center

Phase 2 Unknown
32 enrolled
Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms

NCT03753243 2022-04-20

Neoadjuvant Pembrolizumab Plus Androgen Axis Blockade Prior to Prostatectomy for High Risk Localized Prostate Cancer

Portland VA Medical Center

Phase 2 Recruiting
32 enrolled
Genitourinary

Parkinson Disease 4, Autosomal Dominant Lewy Body, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡